Patients
Confidence in Breast Cancer Therapy Decisions
EndoPredict is a test that helps guide important treatment decisions for your cancer journey.
More Clarity. More Confidence. A Treatment Plan That Fits You.
- If you’ve been diagnosed with breast cancer you have important decisions ahead. One hard challenge is figuring out which treatments you really need.
Gaining clarity about your medical condition is the first step in taking control of your healthcare journey. EndoPredict is a test specifically designed to provide more detailed information about early-stage estrogen receptor positive (ER+) HER2 negative (HER2-) breast cancer.
It could help you and your doctor better understand how your cancer may behave – both in the near future and over the long term.1,2 It also shows whether you are likely to benefit from chemotherapy.3
With EndoPredict, you and your doctor can make informed, personalized decisions about your treatment – so your plan is just right for you.
Early-stage breast cancer
The cancer is limited to the breast and maybe nearby lymph nodes. It has not spread to other parts of the body, which means there are good treatment options and a better chance for recovery.
ER+ (Estrogen Receptor Positive)
The cancer cells grow in response to the hormone estrogen. This means they may respond well to treatments that block or lower estrogen levels, like hormone therapy.
HER2- (HER2 Negative)
The cancer does not have high levels of the HER2 protein, which can cause fast tumor growth. HER2- negative cancers usually grow more slowly and are treated differently from HER2-positive ones.
Why EndoPredict® Matters to You?
- Breast cancer affects about 1 in 8 women worldwide, with over 2 million new cases each year.4
- But not all breast cancers are the same – and not every patient needs the same treatment.5
- For women with early-stage ER+/HER2- breast cancer, 5 years of hormone therapy after surgery is often enough.
- However, some women benefit from longer hormone therapy or adding chemotherapy.
- Deciding on the best approach can be difficult – and that’s where EndoPredict helps.
How EndoPredict® Helps
Every breast cancer is different – not just in how it looks under the microscope, but in how it may behave in the months and years ahead. EndoPredict helps uncover this hidden information by analyzing the biology of your tumor.1-3
EndoPredict helps answer pressing questions:
- How likely is it that my cancer will stay in the breast, or show up again elsewhere in the body? Could it be soon or years from now?
- Could 5 years of hormone therapy after surgery be enough for me?
- Would I benefit from adding chemotherapy to my treatment plan?
By providing key insights, EndoPredict supports personalized treatment decisions. This means you and your doctor can make informed choices with greater confidence – avoiding unnecessary chemotherapy or extended endocrine treatment and focusing on what’s most effective for your unique situation.
“After my diagnosis, I felt unsure which therapy was right for me. My doctor explained that there are different tools to support decisions, which helped me and my care team choose a path that felt right for me.”
Patient feedback
Who Can Benefit?
EndoPredict® is suitable for most women with:
- Early-stage (non-metastatic), ER-positive, HER2-negative breast cancer
- Both premenopausal and postmenopausal patients
- Patients whose cancer has not or only limited spread to the lymph nodes (N0-N1)
To find out whether EndoPredict might be an option for you, please discuss it with your doctor.
Talking to Your Doctor about the EndoPredict® Test
If you think EndoPredict might be right for you, the next step is to talk with your doctor. Preparing for this conversation can help you feel more confident and supported.
Before your appointment, take time to learn about your breast cancer type, possible treatment options, and how biomarker tests like EndoPredict can support decision-making. Bring any relevant information with you, such as the patient guide available for download below, so your doctor can determine if the test is appropriate for your situation.
Remember that your doctor is on your side. You both want what’s best for you and helping successfully manage your cancer is everyone’s top priority. Don’t hesitate to ask questions, express your concerns, or talk about what’s important to you – from side effects to your personal preferences.
Consider inviting a trusted friend or family member to join you – they can provide emotional support and help remember important details. They can also support you in asking questions.
Taking an active role in your care starts with one conversation. Taking this first step by talking to your doctor can open the door to personalized care with tools like EndoPredict.
Learn More About EndoPredict®
Discover detailed information about EndoPredict, find answers to common questions, or get in touch with our team.
Want to Learn More at Your Own Pace?
- All key information in one brochure.
- Easy to read and revisit.
- Download to learn about your options.
References
Filipits M. et al.: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors. Clin. Cancer Res. 2011
Filipits M. et al.: Prediction of Distant Recurrence using EndoPredict among Women with ER+, HER2- Node- Positive and Node-Negative Breast Cancer Treated with Endocrine Therapy Only. Clin Cancer Res. 2019
Sestak I. et al.: Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. Breast Cancer Res Treat. 2019
International Agency for Research On Cancer, WHO, GLOBOCAN 2022. Breast fact sheet, 2022. Accessed on May 28, 2025. https://gco.iarc.fr/today/data/factsheets/cancers/20-Breast-fact-sheet.pdf. 2022
Harbeck N. et al.: A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer. Cancer. 2022;128(11):2036-2047.
